Register entry
Gilead Sciences, Inc.
- Registered sites
- 4
- Drug products
- 50
- Live patents
- 533
- Countries
- 3
- Base
- United States
Authorisation
Registered operations
What the FDA has registered these sites to do. This is the regulatory record, not a marketing claim.
Analytical testingActive ingredient (API) manufactureLabellingFinished drug manufacturePackaging
Sites
Facilities
4| Site | Location | Operations | FEI |
|---|---|---|---|
| Gilead Alberta ULC | EdmontonCanada | Analytical testing, Active ingredient (API) manufacture | 3001027806 |
| GILEAD SCIENCES IRELAND UNLIMITED COMPANY | CarrigtohillIreland | Analytical testing, Labelling, Finished drug manufacture, Packaging | 3006709727 |
| Gilead Sciences, Inc. | Foster City, CAUnited States | Analytical testing | 1000523075 |
| Gilead Sciences, Inc. | La Verne, CAUnited States | Analytical testing, Labelling, Finished drug manufacture, Packaging | 3013189568 |
Exclusivity
Patents
533Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| ATRIPLA | EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE | Apr 2029 |
| BIKTARVY | BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE | Aug 2032 |
| BIKTARVY | BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE | Feb 2033 |
| BIKTARVY | BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE | Dec 2033 |
| BIKTARVY | BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE | Jun 2035 |
| BIKTARVY | BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE | Nov 2036 |
| COMPLERA | EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE | Jan 2033 |
| DESCOVY | EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE | Aug 2032 |
| DESCOVY | EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE | Feb 2033 |
| DESCOVY | EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE | Jun 2036 |
| EPCLUSA | SOFOSBUVIR; VELPATASVIR | Mar 2028 |
| EPCLUSA | SOFOSBUVIR; VELPATASVIR | Sept 2028 |
| EPCLUSA | SOFOSBUVIR; VELPATASVIR | Mar 2029 |
| EPCLUSA | SOFOSBUVIR; VELPATASVIR | Sept 2029 |
| EPCLUSA | SOFOSBUVIR; VELPATASVIR | Sept 2030 |
| EPCLUSA | SOFOSBUVIR; VELPATASVIR | Dec 2030 |
| EPCLUSA | SOFOSBUVIR; VELPATASVIR | Mar 2031 |
| EPCLUSA | SOFOSBUVIR; VELPATASVIR | Jun 2031 |
| EPCLUSA | SOFOSBUVIR; VELPATASVIR | Nov 2032 |
| EPCLUSA | SOFOSBUVIR; VELPATASVIR | May 2033 |
| EPCLUSA | SOFOSBUVIR; VELPATASVIR | Jan 2034 |
| EPCLUSA | SOFOSBUVIR; VELPATASVIR | Jul 2034 |
| GENVOYA | COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE | Aug 2026 |
| GENVOYA | COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE | Oct 2026 |
| GENVOYA | COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE | Feb 2027 |
| GENVOYA | COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE | Apr 2027 |
| GENVOYA | COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE | Sept 2029 |
| GENVOYA | COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE | Mar 2030 |
| GENVOYA | COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE | Apr 2030 |
| GENVOYA | COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE | Oct 2030 |
| GENVOYA | COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE | Aug 2032 |
| GENVOYA | COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE | Oct 2032 |
| GENVOYA | COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE | Feb 2033 |
| GENVOYA | COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE | Apr 2033 |
| HARVONI | LEDIPASVIR; SOFOSBUVIR | Mar 2028 |
| HARVONI | LEDIPASVIR; SOFOSBUVIR | Sept 2028 |
| HARVONI | LEDIPASVIR; SOFOSBUVIR | Mar 2029 |
| HARVONI | LEDIPASVIR; SOFOSBUVIR | Sept 2029 |
| HARVONI | LEDIPASVIR; SOFOSBUVIR | May 2030 |
| HARVONI | LEDIPASVIR; SOFOSBUVIR | Sept 2030 |
| HARVONI | LEDIPASVIR; SOFOSBUVIR | Nov 2030 |
| HARVONI | LEDIPASVIR; SOFOSBUVIR | Dec 2030 |
| HARVONI | LEDIPASVIR; SOFOSBUVIR | Mar 2031 |
| HARVONI | LEDIPASVIR; SOFOSBUVIR | Jun 2031 |
| HARVONI | LEDIPASVIR; SOFOSBUVIR | Sept 2032 |
| HARVONI | LEDIPASVIR; SOFOSBUVIR | Mar 2033 |
| HARVONI | LEDIPASVIR; SOFOSBUVIR | Jan 2034 |
| HARVONI | LEDIPASVIR; SOFOSBUVIR | Jul 2034 |
| LETAIRIS | AMBRISENTAN | Dec 2027 |
| LETAIRIS | AMBRISENTAN | Oct 2031 |
| LIVDELZI | SELADELPAR LYSINE | Sept 2026 |
| LIVDELZI | SELADELPAR LYSINE | Mar 2035 |
| ODEFSEY | EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE | Aug 2032 |
| ODEFSEY | EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE | Feb 2033 |
| SOVALDI | SOFOSBUVIR | Mar 2028 |
| SOVALDI | SOFOSBUVIR | Sept 2028 |
| SOVALDI | SOFOSBUVIR | Mar 2029 |
| SOVALDI | SOFOSBUVIR | Sept 2029 |
| SOVALDI | SOFOSBUVIR | Sept 2030 |
| SOVALDI | SOFOSBUVIR | Dec 2030 |
Catalogue
Marketed products
50Showing 50 of 50.
| Brand | Generic name | Form | Category |
|---|---|---|---|
| - | AZTREONAM | POWDER | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING |
| Biktarvy | bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate | TABLET | NDA |
| Biktarvy | bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate | TABLET | NDA |
| Biktarvy | bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate | TABLET | NDA |
| COMPLERA | emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate | TABLET, FILM COATED | NDA |
| Cayston | aztreonam | KIT | NDA |
| DESCOVY | emtricitabine and tenofovir alafenamide | TABLET | NDA |
| DESCOVY | emtricitabine and tenofovir alafenamide | TABLET | NDA |
| Emtriva | EMTRICITABINE | CAPSULE | NDA |
| Emtriva | EMTRICITABINE | SOLUTION | NDA |
| Epclusa | Velpatasvir and Sofosbuvir | TABLET, FILM COATED | NDA |
| Epclusa | Velpatasvir and Sofosbuvir | TABLET, FILM COATED | NDA |
| Epclusa | Velpatasvir and Sofosbuvir | PELLET | NDA |
| Epclusa | Velpatasvir and Sofosbuvir | PELLET | NDA |
| Genvoya | elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide | TABLET | NDA |
| HEPCLUDEX | BULEVIRTIDE | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | BLA |
| Harvoni | LEDIPASVIR and SOFOSBUVIR | TABLET, FILM COATED | NDA |
| Harvoni | ledipasvir and sofosbuvir | TABLET, FILM COATED | NDA |
| Harvoni | ledipasvir and sofosbuvir | PELLET | NDA |
| Harvoni | ledipasvir and sofosbuvir | PELLET | NDA |
| Letairis | AMBRISENTAN | TABLET, FILM COATED | NDA |
| Letairis | AMBRISENTAN | TABLET, FILM COATED | NDA |
| Livdelzi | SELADELPAR LYSINE | CAPSULE | NDA |
| ODEFSEY | emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide | TABLET | NDA |
| Sovaldi | SOFOSBUVIR | TABLET, FILM COATED | NDA |
| Sovaldi | SOFOSBUVIR | TABLET, FILM COATED | NDA |
| Sovaldi | SOFOSBUVIR | PELLET | NDA |
| Sovaldi | SOFOSBUVIR | PELLET | NDA |
| Stribild | elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate | TABLET, FILM COATED | NDA |
| Sunlenca | LENACAPAVIR SODIUM | TABLET, FILM COATED | NDA |
| Sunlenca | LENACAPAVIR SODIUM | KIT | NDA |
| Sunlenca | LENACAPAVIR SODIUM | KIT | NDA |
| TRODELVY | SACITUZUMAB GOVITECAN | POWDER, FOR SOLUTION | BLA |
| Truvada | emtricitabine and tenofovir disoproxil fumarate | TABLET, FILM COATED | NDA |
| Truvada | emtricitabine and tenofovir disoproxil fumarate | TABLET, FILM COATED | NDA |
| Truvada | emtricitabine and tenofovir disoproxil fumarate | TABLET, FILM COATED | NDA |
| Truvada | emtricitabine and tenofovir disoproxil fumarate | TABLET, FILM COATED | NDA |
| Tybost | COBICISTAT | TABLET, FILM COATED | NDA |
| VEMLIDY | tenofovir alafenamide | TABLET | NDA |
| Veklury | remdesivir | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | NDA |
| Viread | TENOFOVIR DISOPROXIL FUMARATE | TABLET, COATED | NDA |
| Viread | TENOFOVIR DISOPROXIL FUMARATE | POWDER | NDA |
| Viread | TENOFOVIR DISOPROXIL FUMARATE | TABLET, COATED | NDA |
| Viread | TENOFOVIR DISOPROXIL FUMARATE | TABLET, COATED | NDA |
| Viread | TENOFOVIR DISOPROXIL FUMARATE | TABLET, COATED | NDA |
| Vosevi | SOFOSBUVIR, VELPATASVIR, and VOXILAPREVIR | TABLET, FILM COATED | NDA |
| Yeztugo | LENACAPAVIR SODIUM | TABLET, FILM COATED | NDA |
| Yeztugo | LENACAPAVIR SODIUM | KIT | NDA |
| Zydelig | idelalisib | TABLET, FILM COATED | NDA |
| Zydelig | idelalisib | TABLET, FILM COATED | NDA |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.